On the 18th, JUN ZHI Biomedical Co., Ltd. officially signed a Memorandum of Understanding (MOU) with the University of South Australia to jointly promote the clinical application and global expansion of its nano mass spectrometry diagnostic platform, bringing new momentum to the field of precision medicine worldwide.

This world-first “nano-probe mass spectrometry technology” was co-developed by Dr. Yu-Ju Chen of Academia Sinica and Professor Chun-Cheng Lin of National Tsing Hua University. By integrating functionalized nanoparticles with mass spectrometry, the platform enables highly sensitive analysis of multiple protein isoforms in blood samples. Combined with AI algorithms, it provides scientific support for early risk detection of gastrointestinal diseases such as gastric and colorectal cancers, aligning with the preventive medicine philosophy of traditional Chinese medicine—“treating disease before it arises.”

JUN ZHI Biomedical Chairperson Hui-Ju Kuo stated that after eight years of dedicated development and over 2,500 clinical sample tests, the technology has earned strong recognition from leading hospitals in Taiwan. It has already been adopted by more than 60 medical institutions, including Kaohsiung Medical University Hospital, Chi Mei Medical Center, and Fu Jen Catholic University Hospital, offering a non-invasive, rapid, and accurate option for health management.

The initial focus of the collaboration with the University of South Australia will be on gastric cancer detection. Joint clinical trials will be conducted locally in Australia, along with the development of a proteomic database to account for ethnic variation, thereby enhancing the accuracy of the AI-based algorithms. Professor Peter Hoffmann of the University of South Australia noted that this partnership will further strengthen South Australia's foundation in mass spectrometry and precision medicine research, and open new possibilities for early diagnosis of various diseases.

Kuo emphasized, “This is not only a critical step for JUN ZHI Biomedical's international expansion, but also a testament to Taiwan’s biomedical R&D capabilities on the global stage. We believe that nano mass spectrometry will become a core tool in preventive medicine, bringing tangible health benefits worldwide.”

With the launch of this international collaboration and the establishment of overseas research facilities, JUN ZHI Biomedical is redefining the future of disease prediction, setting a new benchmark in cancer screening and health management through solid scientific innovation and a global vision.

Resource: 俊質生醫攜手澳洲南澳大學 推動奈米質譜技術國際臨床應用